ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
103.42
+0.21 (+0.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close103.21
Open102.80
Bid102.00 x 800
Ask103.50 x 1400
Day's Range102.42 - 103.88
52 Week Range51.05 - 121.92
Volume266,598
Avg. Volume665,673
Market Cap3.058B
Beta2.04
PE Ratio (TTM)N/A
EPS (TTM)-13.00
Earnings DateOct 30, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est123.07
Trade prices are not sourced from all markets
  • Array BioPharma Posted Net Loss of $52.4 Million in Q4
    Market Realist2 days ago

    Array BioPharma Posted Net Loss of $52.4 Million in Q4

    On August 14, Array BioPharma (ARRY) announced its fourth quarter and full fiscal 2018 results for the period ended June 30, 2018. The adjusted EPS (earnings per share) for the fourth quarter came in at -$0.17, exceeding analysts’ estimate of -$0.21. Net loss in the fourth quarter of fiscal 2018 was $52.4 million as compared to $29.6 million losses reported in the fourth quarter of fiscal 2017.

  • Is Intercept Pharmaceuticals, Inc. a Buy?
    Motley Fool2 days ago

    Is Intercept Pharmaceuticals, Inc. a Buy?

    This company's leading a race that's drawn a lot of competition.

  • What Analysts Recommend for Array BioPharma Stock
    Market Realist2 days ago

    What Analysts Recommend for Array BioPharma Stock

    Array BioPharma (ARRY) announced its fourth-quarter and full fiscal 2018 results on August 14. That day, ARRY stock registered a decline of ~2.6% and fell further the following day. The decline in stock prices was triggered by the negative investor sentiments due to the Array BioPharma’s fourth-quarter results falling short of estimates. In this article, we’ll look at analysts’ latest recommendations and target prices on ARRY stock over the next 12 months.

  • Thomson Reuters StreetEvents5 days ago

    Edited Transcript of ICPT earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Intercept Pharmaceuticals Inc Earnings Call

  • Investopedia8 days ago

    4 Biotech Stocks That May Fall By as Much as 13%

    Biotech stocks have been hot since the beginning of May, rising by about 13% as measured by the iShares Nasdaq Biotechnology ETF ( IBB), more than double the pace of the S&P 500's rise. Shares of Intercept Pharmaceuticals Inc. ( ICPT) have risen by more than 63% since the beginning of May, while recently posting better-than-expected quarterly results that beat on both the top and bottom lines. The stock has run into a level of technical resistance around $118, posing as the first issue. Additionally, the relative strength index is showing signs that the stock is now overbought, rising above 70 three times since the start of June.

  • Puma Biotechnology: Recent Developments and Recommendations
    Market Realist9 days ago

    Puma Biotechnology: Recent Developments and Recommendations

    In June, the Committee for Medicinal Products for Human Use recommended a favorable opinion on the approval of Puma Biotechnology’s (PBYI) Nerlynx for its commercialization in the European Union for the prolonged adjuvant therapy of adults with early-stage HER2+ (hormone-receptor-positive) breast cancer whose prior adjuvant trastuzumab-based therapy is less than one year from completion.

  • How Puma Biotechnology Performed in Q2 2018
    Market Realist9 days ago

    How Puma Biotechnology Performed in Q2 2018

    Puma Biotechnology (PBYI) released its second-quarter earnings results on August 9. It reported net revenue of $117.3 million in the first half of 2018. Puma Biotechnology’s revenue came primarily from its sales of Nerlynx.

  • 2 Growth Stocks That Could Make You Rich
    Motley Fool10 days ago

    2 Growth Stocks That Could Make You Rich

    Heron Therapeutics and Intercept Pharmaceuticals could both produce market-crushing returns for investors over the next decade. Here's why.

  • Intercept Pharmaceuticals’ Stock Price Rose 17.94% on August 6
    Market Realist12 days ago

    Intercept Pharmaceuticals’ Stock Price Rose 17.94% on August 6

    On August 6, Intercept Pharmaceuticals’ (ICPT) stock price grew ~17.94% to $114.71—compared to the previous day’s closing price of $97.26. On August 6, Intercept Pharmaceuticals’ stock price closed at $114.71, which represents ~125% growth from its 52-week low of $51.05 on February 9.

  • ACCESSWIRE12 days ago

    Today’s Research Reports on Stocks to Watch: Protagonist Therapeutics and Intercept Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Biotech stocks Protagonist Therapeutics and Intercept Pharmaceuticals were heading higher on Monday after positive developments and analyst upgrades. Protagonist ...

  • Why Intercept Pharmaceuticals Stock Is Moving Higher Today
    Motley Fool12 days ago

    Why Intercept Pharmaceuticals Stock Is Moving Higher Today

    Wall Street is warming up to this mid-cap drugmaker.

  • Benzinga13 days ago

    Intercept Pharma Notches 2 Upgrades On Ocaliva Prospects

    Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) reported top- and bottom-line beats last week that prompted two Street analysts to upgrade the stock. The Rating Goldman Sachs analyst Salveen Richter upgraded ...

  • Barrons.com13 days ago

    Small Biotechs See Big Gains as Bluebird, Intercept Fly

    Smaller biotechs are rising, following the announcement of a collaboration between bluebird bio (BLUE) and Regeneron Pharmaceuticals to tackle cancer and a double upgrade for Intercept Pharmaceuticals (ICPT). Bluebird bio (BLUE) is soaring on news that Regeneron Pharmaceuticals said it would make a $100 million investment in the biotech's stock at $238.10 a share, which represents a 59% premium over bluebird's Friday closing price.  The two companies plan to collaborate on new immune cell therapies for cancer treatment over a period of five years.  Bluebird is up 4.2% to $156.26 in recent trading, while Regeneron is falling 0.6% to $392.42. In addition, Intercept Pharmaceuticals (ICPT) was on the receiving end of a double upgrade from Goldman Sachs.

  • Intercept (ICPT) Gains on Solid Q2 Results, Ocaliva Recovers
    Zacks16 days ago

    Intercept (ICPT) Gains on Solid Q2 Results, Ocaliva Recovers

    Intercept (ICPT) gains on a better-than-expected second quarter as loss narrows and sales surpass estimates on a significant recovery in Ocaliva.

  • Bloomberg16 days ago

    Intercept Shares Rise as Drug Sales Recover After Patient Deaths

    Intercept Pharmaceuticals Inc. rose to the highest level since September after the company reported increasing sales of its potential blockbuster Ocaliva, a drug previously linked by U.S. officials to the death of 19 people. Sales of Ocaliva, which is approved to treat a rare liver disease called primary biliary cholangitis, climbed to $43.2 million in the second quarter, the New York-based drugmaker said Thursday. In September, Intercept reported 10 deaths in people who had taken the drug.

  • Intercept (ICPT) Q2 Loss Narrower-Than-Expected
    Zacks17 days ago

    Intercept (ICPT) Q2 Loss Narrower-Than-Expected

    Intercept (ICPT) reports a narrower-than-expected loss in the second quarter of 2018. Revenues tops expectations.

  • See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.
    Markit17 days ago

    See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.

    Short interest is moderately high for ICPT with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding ICPT totaled $70 million.

  • Associated Press17 days ago

    Intercept: 2Q Earnings Snapshot

    The New York-based company said it had a loss of $2.58 per share. The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss ...

  • GlobeNewswire17 days ago

    Intercept Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

    Worldwide Ocaliva net sales of $43.2 million in the second quarter of 2018 Leading Phase 3 NASH program continues to advance: REGENERATE trial in NASH patients with advanced liver fibrosis expected to ...

  • See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.
    Markit19 days ago

    See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.

    Intercept Pharmaceuticals Inc NASDAQ/NGS:ICPT

  • What's in Store for Intercept (ICPT) This Earnings Season?
    Zacks19 days ago

    What's in Store for Intercept (ICPT) This Earnings Season?

    Investors will primarily focus on Ocaliva's performance along with other pipeline developments, when Intercept (ICPT) reports its Q2 results on Aug 2.

  • GlobeNewswire23 days ago

    Intercept to Announce Second Quarter 2018 Financial Results on August 2, 2018 and Present at Upcoming Investor Conference

    NEW YORK, July 26, 2018-- Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, ...

  • GlobeNewswire25 days ago

    Report: Developing Opportunities within Clearwater Paper, Intercept Pharmaceuticals, Community Trust, Community Bank System, Laboratory Corporation of America, and Dicerna Pharmaceuticals — Future Expectations, Projections Moving into 2018

    NEW YORK, July 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clearwater ...

  • Investopedia27 days ago

    3 Hot Biotech Stocks With More Gains Ahead

    Biotech stocks have been surging in 2018 as measured by the SPDR S&P Biotech ETF ( XBI), which is up nearly 18%, easily outperforming the S&P 500 rise of 5%. Despite the recent gains, shares of Regeneron Pharmaceuticals, Inc. ( REGN), Seattle Genetics, Inc. ( SGEN) and Intercept Pharmaceuticals, Inc. ( ICPT) may be poised to rise by as much as 20% in the coming weeks based on technical analysis. Based on the technical chart for the Biotech ETF, the sector may increase by another 9%.

  • 5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates
    Zackslast month

    5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates

    Biotech industry experiences a turnaround in June. Here are five stocks which are expected to beat expectation in Q2.